Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03DKV
|
|||
| Former ID |
DIB007751
|
|||
| Drug Name |
RGB-286638
|
|||
| Synonyms |
GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1], [2] | |
| Company |
GPC Biotech AG
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C29H37Cl2N7O4
|
|||
| Canonical SMILES |
COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6.Cl.Cl
|
|||
| InChI |
1S/C29H35N7O4.2ClH/c1-39-16-13-34-9-11-35(12-10-34)19-20-5-7-21(8-6-20)26-25-27(32-31-26)22-3-2-4-23(24(22)28(25)37)30-29(38)33-36-14-17-40-18-15-36;;/h2-8H,9-19H2,1H3,(H,31,32)(H2,30,33,38);2*1H
|
|||
| InChIKey |
WJVMGQMXUBAAPL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 784210-87-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7744). | |||
| REF 2 | ClinicalTrials.gov (NCT01168882) Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. | |||
| REF 4 | Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.